温阳化积法治疗卵巢癌生化复发患者1例
增强出版One Case of Ovarian Cancer Biochemical Recurrence Treated by Wenyang Huaji Method
扫 描 看 全 文
1.北京中医医院顺义医院肿瘤科,北京101300
2.首都医科大学附属北京中医医院肿瘤科,北京100010
扫 描 看 全 文
杨海宁, 杨雯婧, 陈芋屹, 等. 温阳化积法治疗卵巢癌生化复发患者1例[DB/OL].(2022-08-04)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=29013953&Fpath=home&index=0
Haining YANG, Wenjing YANG, Yuyi CHEN, et al. One Case of Ovarian Cancer Biochemical Recurrence Treated by Wenyang Huaji Method[DB/OL].(2022-08-04)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=29013953&Fpath=home&index=0
杨海宁, 杨雯婧, 陈芋屹, 等. 温阳化积法治疗卵巢癌生化复发患者1例[DB/OL].(2022-08-04)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=29013953&Fpath=home&index=0 DOI:
Haining YANG, Wenjing YANG, Yuyi CHEN, et al. One Case of Ovarian Cancer Biochemical Recurrence Treated by Wenyang Huaji Method[DB/OL].(2022-08-04)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=29013953&Fpath=home&index=0 DOI:
以温阳化积法治疗卵巢癌生化复发患者1例。,病史摘要,2,患者为老年女性,主因“卵巢癌术后5年,复发术后2年”就诊。患者2016年6月因卵巢占位行手术治疗,术后病理:卵巢浆液性乳头状囊性癌,分期ⅢC期,属局部晚期。术后行6周期化疗,并在期间配合中药治疗。此后定期复查评效稳定。2019年8月复查CA125升高,为43.5 U/mL。下腹盆腔CT提示右下腹膜结节较前明显增大,考虑肿瘤复发。2019年9月患者再次行腹膜转移减瘤术,术后行6周期巩固化疗。化疗后复查CA125:5 U/mL。此后定期复查影像学及CA125未见明显进展。2021年2月复查CA125:13.4 U/mL,下腹+盆腔增强CT未见明显影像学复发征象,此后CA125逐渐升高,2021年6月复查CA125:22.9 U/mL,下腹部+盆腔CT可见盆腔腹膜结节状增厚,但较前无明显动态变化。故考虑患者生化复发可能。四诊信息 就诊时患者手足发凉,周身畏寒,时有发热,平均1-2周发作1次。体力尚可,纳眠可,大便不成形,日一次,小便正常。舌淡暗胖,边有齿痕,苔黄腻,脉沉滑。中医病证 卵巢恶性肿瘤正虚毒结证,中医治法 治以温阳化积为法,配以化瘀解毒之品。西医诊断 卵巢恶性肿瘤ⅢC期疗效转归 患者服药后手足发凉明显改善,畏寒发热症状频次逐渐减少至消失,同时体力、饮食等方面亦得到改善,患者生活质量明显提高。同年9月复查时,CA125也出现了下降趋势,10月复查CA125已降至正常范围。本患者自生化复发至今,中药治疗取得了显著的疗效,在缓解症状的同时也有效的控制了肿瘤的复发进展。
One patient with biochemical recurrence of ovarian cancer was treated with Wenyang Huaji method. ,Summary of case history, The patient was an elderly woman, whose the chief complaint was "5 years after surgery for ovarian cancer and 2 years after surgery for recurrence". The patient underwent surgical treatment for ovarian mass in June 2016. Postoperative pathology is ovarian serous papillary cystic carcinoma, stage ⅢC, which is locally advanced. Six cycles of chemotherapy were performed after surgery, and Chinese medicine was used during the period. After that, regular review and evaluation results were stable. In August 2019, the CA125 was 43.5U/ml , and CT of the lower abdomen and pelvis showed that the right lower peritoneal nodule was significantly larger than before, and tumor recurrence was considered. In September 2019, the patient underwent peritoneal metastasis debulking again. And 6 cycles of consolidation chemotherapy were performed postoperatively. The CA125 after chemotherapy was 5 U/mL. After that, the imaging and CA125 were regularly reviewed and no obvious progress was found. The CA125 was 13.4 U/mL in February 2021, no obvious signs of recurrence on imaging of lower abdomen + pelvic enhanced CT. Then the CA125 gradually increased. The CA125 was 22.9 U/ml in June 2021, and lower abdomen + pelvic CT showed pelvic cavity Nodular thickening of the peritoneum, but no obvious dynamic changes. Therefore, the possibility of biochemical recurrence of the patient was considered., Symptoms and signs, At the time of consultation, the patient had cold hands and feet, chills all over the body, and fever from time to time, which occurred once every 1-2 weeks on average. Physical strength is acceptable, sleepiness is acceptable, stool is not formed, once a day, urination is normal. The tongue is pale, dark and fat, with tooth marks on the sides, thin yellow and greasy fur, and slippery pulse.,TCM disease and syndrome:, abdominal mass (positive deficiency and toxin syndrome). ,Western medicine diagnosis:, ovarian malignant tumor. TCM treatment is based on warming yang and eliminating accumulation, with the products of removing blood stasis and detoxification. ,Clinical outcomes, After the treatment, the patient's hands and feet were significantly improved, and the frequency of exogenous chills and fever symptoms gradually decreased to disappear. At the same time, physical strength and diet were also improved, which significantly improved the patient's quality of life. During the review in September of the same year, the CA125 also showed a downward trend, and the CA125 in the review in October had dropped to the normal range. Since the biochemical recurrence of this patient, the traditional Chinese medicine treatment has achieved remarkable curative effect, which not only relieves the symptoms but also effectively controls the recurrence and progression of the tumor.
卵巢癌中医药生化复发温阳化积法肿瘤
Ovarian cancerTraditional Chinese MedicineBiochemical recurrenceWenyang Huaji methodtumor
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4):284-296.
Wikborn C., Pettersson F., Moberg P. J.. Delay in diagnosis of epithelial ovarian cancer[J]. International Journal of Gynecology and Obstetrics, 1996, 52(3):263-267.
Rufford B.D., Jacobs I.J., Menon U. Feasibility of screening for ovarian cancer using symptoms as selection criteria [J]. British Journal of Obstetrics and Gynaecology, 2007,114(1):59-64.
李琳珂,蔡永敏.“龙火”“龙雷之火”“雷火”的辨析及考证[J].中国中医基础医学杂志. 2020, 26(3):299-311.
汪机.汪石山医学全书·石山医案[M].北京:中国中医药出版社,1999.
徐大椿.神农本经百种录[M].北京:学苑出版社,2011.
李瑞林.浅议细辛的用量问题[J].新疆中医药.2021,33(2):62-64.
张雨晴,王蕾.《伤寒杂病论》桂枝干姜药对运用规律探析[J].继续医学教育.2019,33(7):157-160.
王培屹,李菁,李跃军.“以脾为本,五脏相关”的李东垣“阴火理论”[J].辽宁中医杂志.2021,48(4):74-77.
李可.攻癌夺命汤治验录[N].中国中医药报,2006-08-07(006).
郑蕾,何昊,方怡,等.木鳖子抗肿瘤有效作用部位筛选及作用机制探讨[J].中国实验方剂学杂志.2017,23(9):152-157.
李淼,安红梅,沈克平,等.蛇莓抗肿瘤作用及临床研究[J].世界中医药.2019,14(2):505-509.
陈雷,彭骁,胡兵.龙葵抗肿瘤成分及其作用机制研究进展[J].上海中医药杂志.2021,55(2):101-104.
苗耀东,李小江,贾英杰.猫爪草的化学成分及药理作用研究进展[J].中草药.2014,45(11):1651-1654.
0
浏览量
51
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构